Caladrius Biosciences Inc (NASDAQ:CLBS) Short Interest Down 23.6% in October

Caladrius Biosciences Inc (NASDAQ:CLBS) was the target of a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 39,800 shares, a decline of 23.6% from the September 30th total of 52,100 shares. Currently, 0.4% of the company’s shares are short sold. Based on an average trading volume of 13,300 shares, the short-interest ratio is presently 3.0 days.

A hedge fund recently raised its stake in Caladrius Biosciences stock. Renaissance Technologies LLC lifted its stake in Caladrius Biosciences Inc (NASDAQ:CLBS) by 20.6% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 380,336 shares of the biotechnology company’s stock after purchasing an additional 64,988 shares during the quarter. Renaissance Technologies LLC owned about 3.66% of Caladrius Biosciences worth $867,000 as of its most recent SEC filing. Institutional investors and hedge funds own 8.00% of the company’s stock.

CLBS stock traded down $0.06 during mid-day trading on Friday, reaching $2.71. 40,000 shares of the stock traded hands, compared to its average volume of 15,031. The stock has a market capitalization of $27.77 million, a PE ratio of -1.62 and a beta of 1.46. The business has a 50-day moving average price of $2.32 and a two-hundred day moving average price of $2.60. Caladrius Biosciences has a one year low of $2.00 and a one year high of $5.44.

Caladrius Biosciences (NASDAQ:CLBS) last announced its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.47) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.04). As a group, equities analysts anticipate that Caladrius Biosciences will post -1.58 earnings per share for the current year.

A number of research analysts have weighed in on CLBS shares. Zacks Investment Research cut shares of Caladrius Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 14th. ValuEngine upgraded shares of Caladrius Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $8.63.

About Caladrius Biosciences

Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.

Featured Article: What is a Candlestick Chart?

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.